Case of an anti ‐NMDA receptor encephalitis patient responding to cyclophosphamide with significant brain volume recovery
Conclusions] CPM should be considered for non‐responders to first‐line immunotherapy.
Source: Clinical and Experimental Neuroimmunology - Category: Neurology Authors: Shinji Ashida,
Eijirou Tanaka,
Shiori Ogura,
Keiko Maezono,
Yoshinari Nagakane Tags: CASE REPORT Source Type: research
More News: Brain | Brain Cancers | Dyskinesia | Encephalitis | Headache | Immunotherapy | Migraine | Neurology | Psychiatry